Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult

被引：2
作者：
Nolan, Brendan J. [1 ,2 ]
Varadarajan, Suresh [1 ]
Fourlanos, Spiros [3 ,4 ]
Neoh, Sandra L. [1 ,2 ,4 ]
机构：
[1] Northern Hosp, Dept Endocrinol, Epping, Vic 3076, Australia
[2] Austin Hlth, Dept Endocrinol, Heidelberg, Vic, Australia
[3] Royal Melbourne Hosp, Dept Endocrinol & Diabet, Parkville, Vic, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
来源：
AMERICAN JOURNAL OF MEDICINE | 2020年 / 133卷 / 08期
关键词：
diabetes; latent autoimmune diabetes of the adult; SGLT2; inhibitor; diabetic ketoacidosis; EMPAGLIFLOZIN;
D O I：
10.1016/j.amjmed.2019.12.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are increasingly used for the treatment of type 2 diabetes, but have been associated with ketoacidosis. METHODS/RESULTS: We report a case series of three patients with latent autoimmune diabetes of the adult who presented with ketoacidosis, including one case with normal blood glucose levels, in the context of SGLT2 inhibitor use. CONCLUSIONS: Sodium-glucose co-transporter-2 inhibitors should be used with caution and close clinical monitoring in patients with latent autoimmune diabetes of the adult. A clinical risk score permits targeted autoantibody testing and should be undertaken prior to commencement of SGLT2 inhibitors or cessation of insulin. Crown Copyright (C) 2020 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：E422 / E424
页数：3
相关论文
共 18 条
  • [1] Davies MJ, 2018, DIABETOLOGIA, V61, P2461, DOI [10.1007/s00125-018-4729-5, 10.2337/dci18-0033]
  • [2] Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
    Erondu, Ngozi
    Desai, Mehul
    Ways, Kirk
    Meininger, Gary
    [J]. DIABETES CARE, 2015, 38 (09) : 1680 - 1686
  • [3] SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
    Fadini, Gian Paolo
    Bonora, Benedetta Maria
    Avogaro, Angelo
    [J]. DIABETOLOGIA, 2017, 60 (08) : 1385 - 1389
  • [4] A clinical screening tool identifies autoimmune diabetes in adults
    Fourlanos, S
    Perry, C
    Stein, MS
    Stankovich, J
    Harrison, LC
    Colman, PG
    [J]. DIABETES CARE, 2006, 29 (05) : 970 - 975
  • [5] Latent autoimmune diabetes in adults (LADA) should be less latent
    Fourlanos, S
    Dotta, F
    Greenbaum, CJ
    Palmer, JP
    Rolandsson, O
    Colman, PG
    Harrison, LC
    [J]. DIABETOLOGIA, 2005, 48 (11) : 2206 - 2212
  • [6] SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission
    Hamblin, Peter S.
    Wong, Rosemary
    Ekinci, Elif, I
    Fourlanos, Spiros
    Shah, Sonali
    Jones, Alicia R.
    Hare, Matthew J. L.
    Calder, Genevieve L.
    Epa, Dilan Seneviratne
    George, Elizabeth M.
    Giri, Rinky
    Kotowicz, Mark A.
    Kyi, Mervyn
    Lafontaine, Nicole
    MacIsaac, Richard J.
    Nolan, Brendan J.
    O'Neal, David N.
    Renouf, Debra
    Varadarajan, Suresh
    Wong, Jennifer
    Xu, Sylvia
    Bach, Leon A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08) : 3077 - 3087
  • [7] AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS
    Handelsman, Yehuda
    Henry, Robert R.
    Bloomgarden, Zachary T.
    Dagogo-Jack, Sam
    DeFronzo, Ralph A.
    Einhorn, Daniel
    Ferrannini, Ele
    Fonseca, Vivian A.
    Garber, Alan J.
    Grunberger, George
    LeRoith, Derek
    Umpierrez, Guillermo E.
    Weir, Matthew R.
    [J]. ENDOCRINE PRACTICE, 2016, 22 (06) : 753 - 762
  • [8] Latent autoimmune diabetes of the adult: current knowledge and uncertainty
    Laugesen, E.
    Ostergaard, J. A.
    Leslie, R. D. G.
    [J]. DIABETIC MEDICINE, 2015, 32 (07) : 843 - 852
  • [9] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    McMurray, J. J. V.
    Solomon, S. D.
    Inzucchi, S. E.
    Kober, L.
    Kosiborod, M. N.
    Martinez, F. A.
    Ponikowski, P.
    Sabatine, M. S.
    Anand, I. S.
    Belohlavek, J.
    Bohm, M.
    Chiang, C. -E.
    Chopra, V. K.
    de Boer, R. A.
    Desai, A. S.
    Diez, M.
    Drozdz, J.
    Dukat, A.
    Ge, J.
    Howlett, J. G.
    Katova, T.
    Kitakaze, M.
    Ljungman, C. E. A.
    Merkely, B.
    Nicolau, J. C.
    O'Meara, E.
    Petrie, M. C.
    Vinh, P. N.
    Schou, M.
    Tereshchenko, S.
    Verma, S.
    Held, C.
    DeMets, D. L.
    Docherty, K. F.
    Jhund, P. S.
    Bengtsson, O.
    Sjostrand, M.
    Langkilde, A. -M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 1995 - 2008
  • [10] SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications
    Meyer, Emily J.
    Gabb, Genevieve
    Jesudason, David
    [J]. DIABETES CARE, 2018, 41 (04) : E47 - E49
12